● The residents of Puerto Rico decided to join the USA.
During the referendum for joining the United States as a state, the majority of Puerto Rican residents voted in favor.
In total, approximately 500 thousand. Puerto Ricans, yet 7,6 thousand. advocated free association with the United States. 6,7 thousand. residents of the country did not want to change anything.
At the moment, Puerto Rico is a territory, dependent on the United States, where is the power of the American Congress. At the same time, it is the Congress that will determine the status of Puerto Rico.
In total, approximately 500 thousand. Puerto Ricans, yet 7,6 thousand. advocated free association with the United States. 6,7 thousand. residents of the country did not want to change anything.
At the moment, Puerto Rico is a territory, dependent on the United States, where is the power of the American Congress. At the same time, it is the Congress that will determine the status of Puerto Rico.
● Конгресс США намерен ужесточить санкции против РФ
● США призвали арабские страны ослабить блокаду Катара
● Google испытала систему регулировки движения дронов
● Essential startup from former Android creator attracted $ 300 million
● США призвали арабские страны ослабить блокаду Катара
● Google испытала систему регулировки движения дронов
● Essential startup from former Android creator attracted $ 300 million
● Shares of the largest US IT companies fell in price by almost $98 billion
● Росфинмониторинг одобряет создание национальной криптовалюты
● Росфинмониторинг одобряет создание национальной криптовалюты
The Ministry of Finance proposes to equate bitcoin with a commodity
● S7 Airlines and Alfa-Bank launch an innovative blockchain platform
● China's CBRC insists on blockchain regulation in the securities market
● SWIFT profit decreased by 31% in 2016 year
● SoftBank bought the robot manufacturer Boston Dynamics
Стартап Pandora привлек $480 million. от SiriusXM
Gapping down
In reaction to disappointing earnings/guidance: N/A.
Select Tech related names showing additional weakness in pre-mkt:
- AMD -4.4%, NVDA -3%, MOMO -2.5%, ATVI -2.1%, AMAT -1.9%, NFLX -1.8%, TSLA -1.8%
- MU -1.8%, WDC -1.8%, FEYE -1.6%, MSFT -1.6%, FB -1.3%, AMZN -1.1%
Other news:
- CHRS -32.2% (issued a complete response letter for its biologics license application for CHS-1701)
- VALE -1.2% (successfully completed a $ 2 billion syndicated revolving credit facility, which will be available for five years)
Analyst comments:
- P -3.6% (downgraded to Perform from Outperform at Oppenheimer)
- ADBE -2.9% (downgraded to Sell from Hold at Pivotal Research Group)
- AAPL -2% (downgraded to Neutral from Buy at Mizuho)
- SNN -1.1% (downgraded to Sell from Hold at Investec)
- HSBC -0.8% (downgraded to Sell from Hold at Investec)
Gapping up (SCANX) :
Gapping up
In reaction to strong earnings/guidance: N/A.
M&A news:
- SEE +3% (to acquire Miramar Labs for an aggregate transaction value of $20 mln in upfront cash plus contractual rights for potential contingent payments)
Other news:
- TROV +37% (enters into an agreement with AstraZeneca (AZN) to provide Trovera urine ctDNA biomarker test and services)
- ABIL +16.6% (continued volatility in pre-mkt)
- FCSC +16% (FDA has granted Rare Pediatric Disease Designation to FCX-013)
- QIWI +12.7% (still checking)
- APOP +9.1% (receives a formal notice of allowance for patent application No. 14/383,288 covering a key composition of matter and method of use)
- XBIT +7.5% (modestly rebounding following Friday’s declines)
- GNMK +7.5% (receives 510(k) market clearance from the FDA for both its ePlex instrument and Respiratory Pathogen Panel)
- EIGR +5.8% (announces positive data from the Phase 2 multiple-ascending dose study evaluating subcutaneous exendin 9-39)
- MZOR +4.4% (modestly rebounding from last week’s decline)
- GTXI +4.2% (presents prelim data from its Phase 2 clinical trial of enobosarm)
- GE +3.6% (names John Flannery Chairman and CEO; Jeff Immelt to retire at the end of the yearg)
- CNIT +2.8% (signs $1 mln cloud-based ad terminal contract for Anhui Province)
- LDS +2.4% (will replace Yahoo! in the S&P 500)
- TSRO +2.3% (provides update regarding the status of a clinical trial of niraparib sponsored by Janssen Biotech (JNJ); temporary enrollment hold is not due to any safety concerns)
- NVO +1.7% (presents study suggesting switching to Tresiba provides significant reductions in blood glucose and lower rates of hypoglycaemia)
Analyst comments:
- VOD +1.3% (upgraded to Buy from Hold at Argus)
